OBJECTIVE: To review the current state of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance, discuss the promising role of second-generation NNRTIs, and provide insight into their clinical utility. DATA SOURCES: Articles were identified through searches of MEDLINE (May 2000-August 2009) and International Pharmaceutical Abstracts (May 1998-August 2009), using the key words etravirine, rilpivirine, TMC125, TMC278, diarylpyrimidine, NNRTI, and resistance. STUDY SELECTION AND DATA EXTRACTION: Clinical trials, resistance studies, and pharmacokinetic data were selected for review. DATA SYNTHESIS: NNRTIs are an integral class of antiretroviral agents utilized for the treatment of HIV-1 infection. These agents have become preferred therapy options for treatment-naïve individuals per treatment guideline recommendations and have gained increased popularity over protease inhibitor-based antiretroviral therapy. However, available NNRTIs possess inherent characteristics, such as low genetic barrier to resistance and high degree of cross-resistance, that limit their use in HIV therapy. Due to the growing utilization of this highly efficacious antiretroviral class and the increased capability for resistance development, many HIV-infected patients have experienced treatment failure of an NNRTI. Cross-resistance makes other first-generation NNRTI agents unavailable for future use. Etravirine and rilpivirine are second-generation NNRTIs that are not significantly hampered by cross-resistance and possess potent antiretroviral activity against current NNRTI-resistant viral strains. These agents provide new and important therapy options for many HIV-infected patients. CONCLUSIONS: NNRTI resistance is an increasing problem that may impair the chances for therapeutic success in HIV-infected patients. Novel agents such as etravirine and rilpivirine provide new, sensitive options for patients and significantly improve the rate of virologic suppression when appropriately applied.
OBJECTIVE: To review the current state of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance, discuss the promising role of second-generation NNRTIs, and provide insight into their clinical utility. DATA SOURCES: Articles were identified through searches of MEDLINE (May 2000-August 2009) and International Pharmaceutical Abstracts (May 1998-August 2009), using the key words etravirine, rilpivirine, TMC125, TMC278, diarylpyrimidine, NNRTI, and resistance. STUDY SELECTION AND DATA EXTRACTION: Clinical trials, resistance studies, and pharmacokinetic data were selected for review. DATA SYNTHESIS: NNRTIs are an integral class of antiretroviral agents utilized for the treatment of HIV-1 infection. These agents have become preferred therapy options for treatment-naïve individuals per treatment guideline recommendations and have gained increased popularity over protease inhibitor-based antiretroviral therapy. However, available NNRTIs possess inherent characteristics, such as low genetic barrier to resistance and high degree of cross-resistance, that limit their use in HIV therapy. Due to the growing utilization of this highly efficacious antiretroviral class and the increased capability for resistance development, many HIV-infectedpatients have experienced treatment failure of an NNRTI. Cross-resistance makes other first-generation NNRTI agents unavailable for future use. Etravirine and rilpivirine are second-generation NNRTIs that are not significantly hampered by cross-resistance and possess potent antiretroviral activity against current NNRTI-resistant viral strains. These agents provide new and important therapy options for many HIV-infectedpatients. CONCLUSIONS:NNRTI resistance is an increasing problem that may impair the chances for therapeutic success in HIV-infectedpatients. Novel agents such as etravirine and rilpivirine provide new, sensitive options for patients and significantly improve the rate of virologic suppression when appropriately applied.
Authors: Anil R Ekkati; Mariela Bollini; Robert A Domaoal; Krasimir A Spasov; Karen S Anderson; William L Jorgensen Journal: Bioorg Med Chem Lett Date: 2012-01-05 Impact factor: 2.823
Authors: Daniel M Himmel; Nataliya S Myshakina; Tatiana Ilina; Alexander Van Ry; William C Ho; Michael A Parniak; Eddy Arnold Journal: J Mol Biol Date: 2014-05-17 Impact factor: 5.469
Authors: William L Jorgensen; Mariela Bollini; Vinay V Thakur; Robert A Domaoal; Krasimir A Spasov; Karen S Anderson Journal: J Am Chem Soc Date: 2011-09-09 Impact factor: 15.419
Authors: Mariela Bollini; Robert A Domaoal; Vinay V Thakur; Ricardo Gallardo-Macias; Krasimir A Spasov; Karen S Anderson; William L Jorgensen Journal: J Med Chem Date: 2011-11-29 Impact factor: 7.446
Authors: Cyril V Abobo; Lei Wu; Jyothy John; Mathew K Joseph; Theodore R Bates; Dong Liang Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2010-09-29 Impact factor: 3.205
Authors: Allison L Agwu; Jennifer Y Chang; Ryan E Wiegand; John T Wheeling; Beverly A Bohannon; Kenneth L Dominguez Journal: AIDS Patient Care STDS Date: 2014-01 Impact factor: 5.078
Authors: Mariela Bollini; Kathleen M Frey; José A Cisneros; Krasimir A Spasov; Kalyan Das; Joseph D Bauman; Eddy Arnold; Karen S Anderson; William L Jorgensen Journal: Bioorg Med Chem Lett Date: 2013-07-08 Impact factor: 2.823